Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III inhaled mosliciguat trial in pulmonary hypertension associated with interstitial lung disease
ISRCTN12299388Phase 3Recruiting
- Sponsor
- Pulmovant
- Start
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) (3 arms), sponsored by Pulmovant. Primary endpoint: Change in exercise capacity by 6-minute walk distance. Started Aug 2026; status: recruiting.
02
Drugs
mosliciguat
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on ISRCTN12299388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12299388.